|
WO2011074519A1
|
|
Pharmaceutical composition for treatment and prevention of age-related memory impair
|
|
WO2010110408A1
|
|
Dna vaccine for alzheimer's disease
|
|
WO2009125646A1
|
|
Tdp-43-storing cell model
|
|
WO2009008529A1
|
|
Antibody binding specifically to tdp-43 aggregate
|
|
WO2008143354A1
|
|
Pharmaceutical composition for enzyme replacement therapy
|
|
US2010240552A1
|
|
Method for evaluation of drug sensitivity by analysis of pomc gene
|
|
WO2008114787A1
|
|
Antiviral agent
|
|
WO2009028221A1
|
|
Quantitative motor function evaluation system
|
|
EP2123677A1
|
|
Anti-brak (cxcl14) human monoclonal antibody and use thereof
|
|
WO2008114544A1
|
|
Probe for visualizing cell cycle
|
|
WO2008066107A1
|
|
Mental condition measuring method, device, and program
|
|
US2009042181A1
|
|
Nucleic acid and gene derived from novel HCV strain and replicon-replicating cell using said gene
|
|
WO2007099869A1
|
|
Therapeutic and preventive agent for hcv
|
|
WO2007066794A1
|
|
Brak-knockout nonhuman animal
|
|
BRPI0618583A2
|
|
highly functional enzyme having modified substrate specificity
|
|
WO2006123644A1
|
|
Int6 PROTEIN INVOLVED IN HYPOXIA STRESS INDUCTION AND USE THEREOF
|
|
WO2006090918A1
|
|
Diabetes model animal
|
|
EP1859676A1
|
|
Hairless transgenic animal
|
|
CN101142484A
|
|
Method of detecting target substances
|
|
EP2078749A1
|
|
Method of evaluating drug sensitivity by analyzing the mu-opioid receptor gene
|
